Orbital Therapeutics
Orbital Therapeutics is an RNA medicines biotechnology company building a platform that combines RNA technology, delivery methods, data science and automation to develop medicines in next-generation vaccines, immunomodulation and protein replacement. Its lead program, OTX-201, is an investigational in vivo CAR T-cell therapy targeting autoimmune disease through B cell depletion. Founded in 2022 as a spin-out from Beam Therapeutics, Orbital was acquired by Bristol Myers Squibb in December 2025 for $1.7 billion ($1.5 billion net of cash acquired).
Acquired
Orbital Therapeutics has been acquired
This company is no longer available on our private secondary market.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2022
Employees
11–50
Total Funding
$270M
1 rounds
Secondary Signals (Note: SetterVC does not verify the accuracy of these)
1 signalBristol Myers Squibb completed its all-cash acquisition of Orbital Therapeutics for $1.7B ($1.5B net of cash acquired)
Company now BMS-owned; no private-market secondary liquidity remains
Funding
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $270M across 1 rounds
Last updated 10-09-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Apr 26, 2023 | Series A Press release | $270M | — | ARCH Venture Partners |
Prominent Investors
Leadership
Ron Philip
Chief Executive Officer
Giuseppe Ciaramella
Co-Founder
Jonathan Piazza
Chief Financial Officer
Niru Subramanian
Chief Operating Officer
Gilles Besin
Chief Scientific Officer
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.